Based on latest news reports, majority of South Korean pharmaceutical companies are increasing phase-three clinical trials of their key products in China. Experts attribute that the company have implemented the latest development in order to seek advantage from the world's second largest bio market.
In the wake of the situation, Samsung Bioepis Co. is seeking approval from Chinese health authorities for the final stage of clinica....
Tags : Samsung Bioepis, phase-three clinical trials, China, South Korean pharmaceutical companies,
comments (0)